231 related articles for article (PubMed ID: 35209781)
21. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Loscocco GG; Vannucchi AM
Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
[TBL] [Abstract][Full Text] [Related]
22. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
23. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
24. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
26. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
[TBL] [Abstract][Full Text] [Related]
27. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
28. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
Singh JA
BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
[TBL] [Abstract][Full Text] [Related]
29. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
30. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
31. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
32. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
Atzeni F; Gozza F; Riva A; Alciati A; Galloway J
Expert Opin Pharmacother; 2023 Apr; 24(6):679-689. PubMed ID: 36946287
[TBL] [Abstract][Full Text] [Related]
33. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
34. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
36. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
37. JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Tokareva K; Reid P; Yang V; Liew D; Peterson AC; Baraff A; Giles J; Singh N
Expert Rev Clin Immunol; 2023; 19(11):1385-1397. PubMed ID: 37596779
[TBL] [Abstract][Full Text] [Related]
38. Comparing available JAK inhibitors for treating patients with psoriasis.
Funk PJ; Perche PO; Singh R; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):281-294. PubMed ID: 35129030
[TBL] [Abstract][Full Text] [Related]
39. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]